New combo therapy shows promise for returning throat cancer
NCT ID NCT03930498
First seen May 15, 2026 · Last updated Jun 22, 2026 · Updated 8 times
Summary
This Phase 2 trial tests a PD-1 antibody (toripalimab) combined with chemotherapy (cisplatin and gemcitabine) and radiation in 68 patients with high-risk recurrent nasopharyngeal carcinoma who cannot have surgery. The goal is to see if this approach improves overall survival and disease control. Researchers are also monitoring side effects and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NASOPHARYNGEAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (PD-1 antibody) plus cisplatin and gemcitabine chemotherapy, followed by intensity-modulated radiotherapy
What this could lead to
If successful, this combination could offer a new treatment option for patients with recurrent nasopharyngeal carcinoma who cannot have surgery, potentially improving survival and disease control.
What could go wrong
This is a small, single-arm Phase 2 trial, so results are preliminary and may not apply to all patients. Side effects from immunotherapy and chemotherapy can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.